If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for ...

SpringWorks Therapeutics (SWTX) gains EMA panel endorsement for Mirdametinib, a treatment for neurofibromatosis type 1. Read ...

German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics for around $3.9 billion, expanding its portfolio of rare disease and cancer treatments ...

Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 billion, a deal that could give it access to a recently approved rare ...

45. After months of discussion, Germany’s Merck KGaA said Monday it would buy SpringWorks Therapeutics for $47 a share in cash, a deal with an equity value of nearly $4 billion. The ...

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) shares are trading higher on Monday after the company inked a deal to be acquired by Merck & Company, Inc. (NYSE:MRK) for $47 per share in cash. The ...

Merck KGaA is nearing a deal to acquire SpringWorks Therapeutics Inc., people familiar with the matter said. An announcement may come as soon as Monday, the people said, asking not to be ...

SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to loss of $1.18 per share a year ago.

SpringWorks Therapeutics brings to Merck KGaA two FDA-approved drugs, both currently under regulatory review in Europe. Beyond their initial applications in rare tumors, these small molecules are ...

SpringWorks Therapeutics, Inc. announced that it expects the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) to issue an opinion on its marketing ...

The active substance of Ezmekly, mirdametinib, is a selective, non-competitive mitogen-activated protein kinase 1 and 2 (MEK ...